Raltegravir Information

Raltegravir is an antiretroviral medication used to treat HIV infections. It works by blocking the action of an enzyme necessary for viral replication.
Category
Drug
Where to get
Available in pharmacies with a prescription.
Applicable for
Prepared by Shruti Sahoo, reviewed by Dr. Eugene Smith

Raltegravir FAQ

What is raltegravir?

Raltegravir (brand names: Isentress and Isentress HD) is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in adults and children. One form of raltegravir, Isentress, is approved for adults and children weighing at least 4 lb and 4 oz (2 kg).

Does raltegravir work against HIV?

Raltegravir is from a class of drugs known as integrase inhibitors. Your doctor will prescribe raltegravir as part of your HIV treatment, along with antiretrovirals from another class of drugs. It is important to take all the drugs as prescribed, every day. Each drug class works against HIV in a different way.

What drugs affect raltegravir?

Many drugs can affect raltegravir, especially: HIV or AIDS medicine-- etravirine, ritonavir, tipranavir, zidovudine; a "statin" cholesterol-lowering medicine--Crestor, Lipitor, Pravachol, Vytorin, Zocor, and others. This list is not complete and many other drugs may affect raltegravir.

Is raltegravir a integrase inhibitor?

Raltegravir was the first integrase inhibitor to receive approval in the United States in October 2007. It was developed by Merck and reported by Summa et al. in the Journal of Medicinal Chemistry. Raltegravir significantly alters HIV viral dynamics and decay and further research in this area is ongoing.

Raltegravir References

If you want to know more about Raltegravir, consider exploring links below:

Explore Related Topics

What are the implications of antiviral resistance on HIV management?

Dive into the implications of antiviral resistance on HIV management, including challenges in treatment efficacy, patient outcomes, and public health concerns. Share your perspectives on the impact of antiviral resistance and potential solutions to address this issue.